Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
1. Measured by its ability to inhibit Fas Ligand induced apoptosis of Jurkat human acute T cell leukemia cells. The ED50 for this effect is typically 0.2-0.8 µg/mL in the presence of 20 ng/mL recombinant human Fas ligand. 2. Measured by its binding ability in a functional ELISA. Immobilized human His-FASLG (Cat:10244-H07Y) at 10 µg/ml (100 µl/well) can bind Cynomolgus FAS-Fc. The EC50 of Cynomolgus FAS-Fc is 0.06-0.14 µg/ml.
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from sterile PBS, pH 7.4
Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
CD95 / FAS is a member of the TNF-receptor superfamily. This receptor contains a death domain. It has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. The interaction of this receptor with its ligand allows the formation of a death-inducing signaling complex that includes Fas-associated death domain protein (FADD), caspase 8, and caspase 10.